This phase I/II trial is testing a new oral cancer drug (LOXO-292) for the treatment of children that have advanced solid- or primary central nervous system- cancer.
This trial is treating patients with advanced solid cancer or a primary cancer of the central nervous system (CNS).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Loxo Oncology, Inc.
This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase 1, eligible patients will be enrolled using a rolling 6 dose escalation scheme, with the starting dose of LOXO-292 being 160mg, twice daily (. equivalent to an adult recommended phase 2 dose). Once maximum tolerated dose or recommended phase 2 dose is identified in phase 1 of this trial, patients will be enrolled to one of four phase 2 dose expansion cohorts, depending on tumour histology and genotype. The cycle length for both phase 1 and phase 2 will be 28 days.
Recruiting Hospitals Read More